The changes in HNSCC cell lines (e.g., CAL-27 cetuximabR) after being treated with Cetuximab (500 ug/ml) for at least 2 months. We used LC-MS/MS to identify the main acetylation sites in resistance cell lines. In this study, it was found that the acetylation of STAT1 might hinder the downstream signaling of IFN-γ

ABSTRACT: Recent clinical trials revealed that prior use of Cetuximab may interfere with ICB efficacy. In this study, STAT1 protein levels changed after continued Cetuximab treatment (500 ug/ml). We used LC-MS/MS to compare the acetylation sites in wild-type and resistant cells. We proposed that the acetylation of STAT1 may impair IFN-γ response.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Po-Hsien Chiu  

LAB HEAD: Muh-Hwa Yang

PROVIDER: PXD054332 | Pride | 2025-12-29

REPOSITORIES: Pride